Category: Include on Menu

Ten-League International Holdings Limited (NASDAQ:TLIH), a Singapore-based provider of turnkey project solutions for the port, construction, civil engineering and underground foundation sectors, issued upbeat financial guidance for fiscal year 2025, citing robust demand tied to major infrastructure developments in Singapore. The company, which supplies heavy equipment, spare parts and engineering consultancy services, said it expects…

Nexalin Technology, Inc. (NASDAQ:NXL) has initiated its pivotal HALO Clarity clinical trial, a key step toward a planned de novo submission to the U.S. Food and Drug Administration seeking clearance for its insomnia treatment technology. The study will evaluate the company’s non-drug Deep Intracranial Frequency Stimulation (DIFS) platform, which Nexalin is positioning as a potential…

Klotho Neurosciences, Inc. (NASDAQ:KLTO) announced the launch of a new genomics diagnostics initiative centered on two epigenetics-based tests designed to support its clinical trials and expand applications in longevity research and biological aging assessment. The company said the tools aim to improve understanding of the relationship between chronological age and biological age while enabling more…

Protara Therapeutics (NASDAQ:TARA) on February 23, 2026, announced updated interim data from its ongoing Phase 2 ADVANCED-2 trial evaluating intravesical TARA-002 in patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ who are either BCG-unresponsive or BCG-naïve. The open-label study results, based on a data cutoff of January 28, 2026, will be…

PTL Limited (NASDAQ:PTLE) said on February 24, 2026, that it has secured approval to implement a 1-for-80 consolidation of its Class A and Class B ordinary shares, a move aimed at restoring compliance with Nasdaq’s minimum bid price requirement and preserving its listing on the Nasdaq Capital Market. The Hong Kong-based marine fuel logistics company…

Palvella Therapeutics (NASDAQ:PVLA) shares climbed about 15% on Tuesday after the company announced positive topline data from its Phase 3 SELVA clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations (mLM). The late-stage study achieved its primary endpoint, demonstrating a statistically significant improvement on the Microcystic Lymphatic Malformation Investigator…

Shoals Technologies Group, Inc. (NASDAQ:SHLS) shares fell 11.21% in pre-market trading Tuesday after the company reported mixed fourth-quarter results, with weaker-than-expected earnings overshadowing a revenue beat and upbeat forward guidance. The electrical balance-of-system solutions provider posted adjusted earnings per share of $0.10, missing analyst forecasts of $0.13 for the quarter. Revenue, however, rose strongly, climbing…

Ideal Power Inc. (NASDAQ:IPWR) shares dropped 16.9% on Tuesday after the company unveiled plans for an underwritten public offering alongside a concurrent private placement expected to generate roughly $14.0 million in gross proceeds. The Austin, Texas–based semiconductor developer said it priced a public offering of 4,458,736 shares of common stock, or pre-funded warrants in lieu…

BioRestorative Therapies, Inc. (NASDAQ:BRTX) said Tuesday that Australia’s intellectual property authority has approved a key patent application covering its ThermoStem® technology, expanding global protection for the company’s stem cell–based treatment approach targeting obesity and metabolic disorders. The allowance, granted by IP Australia under Patent Application No. 2020265664, relates to “Non-naturally occurring three-dimensional (3D) brown adipose-derived…